Eli Lilly and Company (NYSE:LLY) Stock Gets Price Target Increase from Scotiabank

Key Points

• Scotiabank raised Eli Lilly’s price target from $1,300 to $1,605 and maintained a “sector outperform” rating, implying 13.07% upside from the prior close.
• Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48 versus the $5.68 consensus estimate. Analysts broadly remain bullish, with a “Moderate Buy” consensus rating and an average price target of $1,391.29.
• Growth is being driven by diabetes and obesity drugs, while the company faces pricing pressure: realized prices fell about 15%, although volume growth offset the decline, and some quarterly benefits may not recur.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its target price increased by investment analysts at Scotiabank from $1,300.00 to $1,605.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a "sector outperform" rating on the stock. Scotiabank's price target suggests a potential upside of 13.07% from the company's previous close.

A number of other research analysts have also weighed in on the company. Truist Financial reaffirmed a "buy" rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an "outperform" rating in a report on Friday. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Monday, September 28th. Argus raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a research report on Friday. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,391.29.

Eli Lilly and Company Stock Performance

LLY traded up $45.72 on Friday, hitting $1,419.42. The company's stock had a trading volume of 3,114,127 shares, compared to its average volume of 2,933,308. Eli Lilly and Company has a 12 month low of $834.19 and a 12 month high of $1,449.68. The firm has a market cap of $1.34 trillion, a P/E ratio of 47.57, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company's 50 day simple moving average is $1,194.34 and its 200-day simple moving average is $1,090.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.68 by $1.80. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the business posted $7.02 earnings per share. The business's quarterly revenue was up 38.6% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 33.22 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Marshall & Sterling Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after acquiring an additional 15 shares in the last quarter. Torren Management LLC grew its position in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company's stock worth $37,000 after purchasing an additional 25 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth approximately $42,000. Foresight Capital Management Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter worth $49,000. Finally, Caitlin John LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $64,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q3 results: Lilly reported revenue of $24.4 billion, up approximately 39% year over year, while adjusted EPS of $7.48 substantially exceeded analyst expectations. Lilly Q3 2026 results
• Positive Sentiment: GLP-1 sales remained the primary catalyst: Mounjaro revenue rose 65% to $10.7 billion and Zepbound generated $5.35 billion, reinforcing Lilly’s leadership in diabetes and obesity treatments. Combined sales exceeded $16 billion. Tirzepatide Q3 sales
• Positive Sentiment: Higher outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion. Expanding Medicare access, middle-income demand and continued obesity-drug adoption supported the improved outlook. Lilly earnings call highlights
• Positive Sentiment: Pipeline momentum improved: Positive Phase 3 results for experimental obesity and diabetes drug retatrutide versus Ozempic strengthened expectations for Lilly’s next generation of metabolic medicines. The FDA also approved additional Mounjaro cardiovascular-risk labeling and once-weekly basal insulin Onswik. Retatrutide trial results
• Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target from $1,500 to $1,600 and maintained an “outperform” rating, signaling confidence that earnings momentum can continue.
• Neutral Sentiment: Lilly’s quarter included roughly $900 million of benefits from Jardiance milestones and favorable rebate and discount adjustments, factors that may not recur.
• Negative Sentiment: Pricing and cost risks remain: Realized prices declined about 15%, with volume growth doing the work of offsetting lower prices. Lilly also recorded approximately $4.2 billion in acquired in-process research-and-development charges, while management acknowledged ongoing pricing pressure. Reuters Lilly outlook report

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.